Sorafenib-200
| Quantity | Discount | You Save |
|---|---|---|
| 2 | $30.00 | Up to $60.00 |
| 3 | $35.00 | Up to $105.00 |
| 4 | $40.00 | Up to $160.00 |
| 5 | $45.00 | Up to $225.00 |
Sorafenib 200 mg is a medication used primarily in the treatment of certain types of cancers, including kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), and thyroid cancer (differentiated thyroid carcinoma). It belongs to a class of drugs known as multikinase inhibitors and works by slowing down or stopping the growth of cancer cells.
Product Details:
Always consult your treating doctor or specialist before taking the medication or making any changes to your treatment(s).
| Mechanism of Action | Sorafenib is a multikinase inhibitor that inhibits tumor growth and angiogenesis by inhibiting intracellular Raf kinases (CRAF, BRAF, and mutant BRAF), and cell surface kinase receptors (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, cKIT, FLT-3, RET, and RET/PTC) |
| Drug Formulation | Sorafenib is administered orally and is formulated as a film-coated tablet2. Each tablet contains 200 mg of Sorafenib |
| PharmacoKinetics | Absorption: Sorafenib is rapidly absorbed after oral administration with a peak plasma concentration at ~3 hours Distribution: Sorafenib is extensively distributed into tissues and highly protein bound, predominantly to albumin and α1-glycoprotein (AGP), which is translated into a large volume of distribution Metabolism: Sorafenib is primarily metabolized in the liver, via CYP3A4 (primarily oxidated to the pyridine N-oxide; active, minor) and UGT1A9 (glucuronidation) Excretion: Sorafenib is mainly eliminated through the feces (77%, 51% of dose as unchanged drug); urine (19%, as metabolites) |
| Adverse Reactions | Patients may experience weight loss, nausea/vomiting, diarrhea, loss of appetite, changes in taste, dry skin, mouth sores, hair loss, voice changes, or tiredness. If any of these effects last or get worse, patients should tell their doctor or pharmacist promptly |
| Contraindications | Use of Sorafenib tablets is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of sorafenib tablets. Sorafenib tablets in combination with carboplatin and paclitaxel are contraindicated in patients with squamous cell lung cancer |
| Breast feeding | The manufacturer recommends that breastfeeding be discontinued during sorafenib therapy and for 2 weeks after the last dose |
| Fertility | Sorafenib has caused fertility problems in male animals. Fertility problems may affect being able to father a child. If you have questions, talk with your doctor |
| Drug Interactions | Sorafenib has severe interactions with the following drugs: dronedarone, lefamulin, pimozide, saquinavir, thioridazine, ziprasidone |
| Duration of Action | Approximately 25 to 48 hours |
| Dosage | The recommended dosage of sorafenib tablets is 400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity Doses of 400 mg should be administered twice daily Keep all medications away from children and pets |
| Storage | Do not store above 30°C Store in the original package in order to protect from moisture |
| Overdose | Patients who ingest more than the recommended dosage should be closely monitored and given appropriate supportive treatment. |
| Warnings | Pregnancy: Women of childbearing potential should be advised to avoid becoming pregnant |
All information given on this website is strictly for information only. Published information may not be up to date or completely accurate.
By no means does any information here constitute a medical advise or reference. Please always consult your doctor for guidance.
No customer reviews for the moment.
